Does Lenzing (VIE:LNZ) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. As with many other companies Lenzing Aktiengesellschaft (VIE:LNZ) makes use of debt. But the more important question is: how much risk is that debt creating?

Advertisement

When Is Debt Dangerous?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

What Is Lenzing's Net Debt?

You can click the graphic below for the historical numbers, but it shows that Lenzing had €1.94b of debt in March 2025, down from €2.32b, one year before. However, because it has a cash reserve of €428.8m, its net debt is less, at about €1.51b.

debt-equity-history-analysis
WBAG:LNZ Debt to Equity History June 12th 2025

How Healthy Is Lenzing's Balance Sheet?

We can see from the most recent balance sheet that Lenzing had liabilities of €999.9m falling due within a year, and liabilities of €2.19b due beyond that. Offsetting this, it had €428.8m in cash and €308.9m in receivables that were due within 12 months. So it has liabilities totalling €2.46b more than its cash and near-term receivables, combined.

This deficit casts a shadow over the €1.06b company, like a colossus towering over mere mortals. So we'd watch its balance sheet closely, without a doubt. At the end of the day, Lenzing would probably need a major re-capitalization if its creditors were to demand repayment.

View our latest analysis for Lenzing

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).

While Lenzing's debt to EBITDA ratio (3.6) suggests that it uses some debt, its interest cover is very weak, at 0.82, suggesting high leverage. In large part that's due to the company's significant depreciation and amortisation charges, which arguably mean its EBITDA is a very generous measure of earnings, and its debt may be more of a burden than it first appears. So shareholders should probably be aware that interest expenses appear to have really impacted the business lately. One redeeming factor for Lenzing is that it turned last year's EBIT loss into a gain of €123m, over the last twelve months. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Lenzing can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. So it's worth checking how much of the earnings before interest and tax (EBIT) is backed by free cash flow. During the last year, Lenzing produced sturdy free cash flow equating to 76% of its EBIT, about what we'd expect. This free cash flow puts the company in a good position to pay down debt, when appropriate.

Our View

On the face of it, Lenzing's interest cover left us tentative about the stock, and its level of total liabilities was no more enticing than the one empty restaurant on the busiest night of the year. But on the bright side, its conversion of EBIT to free cash flow is a good sign, and makes us more optimistic. Looking at the bigger picture, it seems clear to us that Lenzing's use of debt is creating risks for the company. If all goes well, that should boost returns, but on the flip side, the risk of permanent capital loss is elevated by the debt. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. To that end, you should be aware of the 2 warning signs we've spotted with Lenzing .

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About WBAG:LNZ

Lenzing

Produces and markets regenerated cellulosic fibers for textiles and nonwovens.

Undervalued with imperfect balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
GANX logo
Lou_Basenese on Gain Therapeutics ·

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Fair Value:US$7.673.0% undervalued
21 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.235.0% undervalued
51 users have followed this narrative
1 users have commented on this narrative
17 users have liked this narrative
TE
BUSER logo
TechMegaTrends on Bambuser ·

Bambuser is today the only listed company in Europe that simultaneously possesses an 85% gross margin, proprietary AI infrastructure for the

Fair Value:SEK 238.2687.2% undervalued
33 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
HE
HedgeY
CSTM logo
HedgeY on Constellium ·

Constellium jet another cyclical aluminum processor, or a mispriced aluminum platform?

Fair Value:US$3412.8% undervalued
5 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative

Updated Narratives

FA
ORGABIO logo
FA_Trader on Orgabio Holdings Berhad ·

Orgabio: A niche beverage manufacturer that is starting to show stronger scale, improving margins, and clearer earnings traction

Fair Value:RM 0.4839.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TH
LMT logo
TheBestInvestor on Lockheed Martin ·

Orbit + Aero + Defense

Fair Value:US$673.889.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JI
BFBIO logo
jibran5237 on BF Biosciences ·

BFBIO is a long-duration growth platform

Fair Value:PK₨554.0472.2% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3956.4% overvalued
49 users have followed this narrative
3 users have commented on this narrative
42 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3128.4% undervalued
1363 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
RO
Robbo
TSLA logo
Robbo on Tesla ·

The academically fascinating Tesla

Fair Value:US$301.2k% overvalued
38 users have followed this narrative
11 users have commented on this narrative
32 users have liked this narrative